Financial Performance - The company's operating revenue for the current period is ¥634,047,833.60, a decrease of 21.19% compared to the same period last year[20]. - Total operating revenue for the current period is $634.05 million, down 21.14% from $804.53 million in the previous period[33]. - Net profit attributable to shareholders for the current period is ¥42,101,946.61, down 51.62% year-over-year[20]. - Net profit for the current period is $41.85 million, a decrease of 51.66% compared to $86.55 million in the previous period[34]. - Basic and diluted earnings per share are both ¥0.02, down 60.00% from ¥0.05 in the previous year[20]. - The net profit after deducting non-recurring gains and losses is -¥3,289,938.74, representing a decline of 104.29% compared to the previous year[20]. Cash Flow - Net cash flow from operating activities was CNY 159,451,304.75, a slight increase from CNY 149,627,750.29, reflecting a growth of approximately 5.5%[14]. - Cash flow from financing activities generated a net inflow of CNY 603,707,509.29, compared to a net outflow of CNY -4,572,083.35 in the previous period[15]. - The company reported a net cash inflow from investing activities of CNY 81,685,962.84, a significant recovery from a net outflow of CNY -118,848,272.85 in the previous period[14]. - Net cash flow from investing activities improved by 168.73% to 81,685,962.84 from -118,848,272.85 mainly due to the recovery of investments and dividends[46]. - Net cash flow from financing activities increased significantly by 13,304.21% to 603,707,509.29 from -4,572,083.35 due to increased bank borrowings[46]. Assets and Liabilities - Total liabilities increased to CNY 2,912,033,729.61, up from CNY 2,288,184,973.02, representing a growth of approximately 27.2% year-over-year[10]. - The company’s total assets reached CNY 9,058,797,473.33, up from CNY 8,393,099,770.24, representing an increase of approximately 7.9%[10]. - Current assets totaled 4,027,776,667.20, up from 3,245,690,461.75, indicating a significant increase in liquidity[50]. - Cash and cash equivalents increased to 2,305,531,103.61 from 1,490,815,956.57, reflecting improved cash management[50]. - Total assets rose to 9,058,797,473.33 from 8,393,099,770.24, indicating growth in the company's asset base[50]. - Non-current assets decreased to 5,031,020,806.13 from 5,147,409,308.49, showing a reduction in long-term investments[50]. Shareholder Information - The company reported a total of 32,095 common shareholders at the end of the reporting period[27]. - The largest shareholder, Zhejiang Donggang Industrial Co., Ltd., holds 32.37% of the shares, totaling 523,982,587 shares[27]. - Shareholders' equity attributable to the parent company is ¥6,150,080,587.84, a slight increase of 0.24% compared to the previous year[20]. Operating Costs and Expenses - Total operating costs decreased to $642.13 million, a reduction of 9.25% from $708.00 million in the previous period[33]. - Financial expenses increased significantly to $24.96 million, up 547.97% from $3.85 million in the previous period, primarily due to exchange losses from the depreciation of the US dollar[44]. - Operating expenses increased by 96.56% to 245,032.99 from 124,663.16 primarily due to an increase in fixed asset scrapping[46]. - Income tax expenses decreased by 84.46% to 2,221,604.16 from 14,293,732.25 due to a reduction in total profit[46]. Foreign Exchange and Other Income - The company experienced significant foreign exchange losses due to large fluctuations in exchange rates during the reporting period[41]. - Non-operating income includes government subsidies of ¥3,564,265.41 and gains from the disposal of non-current assets of ¥8,248,695.14[21]. - Investment income rose to $20.09 million, an increase of 244.93% from $5.82 million in the previous period, mainly due to received dividends[44]. - The company reported a significant increase in asset disposal gains to $8.30 million, up 5023.79% from $162,040.17 in the previous period[44].
海翔药业(002099) - 2023 Q1 - 季度财报